SKYSCRAPER-06 evaluating tiragolumab plus Tecentriq and chemotherapy didn't meet the first endpoints of progression-free survival at major evaluation and general survival at first...
Lori Wirth, MD, affiliate professor, drugs, Harvard Medical College; medical director, Heart for Head and Neck Cancers; Massachusetts Normal Hospital, discusses the section...
Neuroendocrine tumors, together with small cell lung most cancers and neuroendocrine prostate most cancers, are very aggressive with excessive possibilities of spreading. Nevertheless,...
